Artimplant: First case studies on Artelon(R) foot applications.VASTRA FROLUNDA, Sweden -- At the 2007 annual meeting for the Swedish Society of Foot Surgeons case studies on Artelon[R] foot applications were presented. Dr. Liliane Helger at Sahlgrenska University Hospital The Sahlgrenska University Hospital (swe: Sahlgrenska Universitetssjukhuset) is a university hospital system in Gothenburg, Sweden with a staff of 17,000 people. It is also a teaching hospital in medicine for the Göteborg University, with the Sahlgrenska Academy as the Molndal (SU) presented the first clinical case reports on spring ligament spring ligament n. A dense fibroelastic ligament in the foot extending from the calcaneus to the navicular bone and supporting the head of the talus. repair with Artelon[R] Tissue Reinforcement*. The first patient received treatment in March 2006. All patients have been successfully treated without complications to date. Dr. Helger also reported that she has treated a patient suffering from osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. in the MTP (1) (Message Transfer Part) See SS7. (2) (Media Transfer Protocol) A Microsoft enhancement to the picture transfer protocol (PTP), starting with Windows Media Player 10 in Windows XP. joint with an Artelon[R] MTP Spacer. In addition, Dr. Jan Lidstrom, SU, informed about using Artelon[R] Tissue Reinforcement for repair of Achilles tendon rerupture. CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Hans Rosen said: "In accordance with our plan we are collecting data to further widen the use of Artelon[R] Tissue Reinforcement in addition to the main indication - rotator cuff repair. Spring foot ligament and Achilles tendon repair are two very interesting applications where the unique properties of Artelon[R] offers the surgeon new opportunities for unmet clinical needs. The data received so far is very encouraging. The number of cases is still small and it takes time to establish new products on the market. However, the case reports confirm the opportunity to expand the number of indications for Artelon[R] Tissue Reinforcement." *Artelon[R] Tissue Reinforcement is marketed in the Nordic countries by Artimplant AB (STO:ARTIB) and exclusive in the rest of the world by Arthrotek, Inc., a Biomet Company, under the trademark SportMesh[TM] Soft Tissue Reinforcement for reinforcement of rotator cuff tears. In Europe, the CE marked Artelon[R] Tissue Reinforcement/SportMesh[TM] Soft tissue Reinforcement is intended for use in general surgical procedures for reinforcement of soft tissue. It is also intended for reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery including reinforcement of rotator cuff, patellar patellar of or pertaining to the patella. patellar cartilage a cartilaginous process borne on the medial side of the patella of horses and cattle. , Achilles, biceps, quadriceps or other tendons. In USA SportMesh[TM] Soft Tissue Reinforcement is intended for use in general surgical procedures for reinforcement of soft tissue. It is also intended for reinforcement of soft tissue that is repaired by suture or suture anchors, limited to the supraspinatus, during rotator cuff surgery. Artelon[R] is a registered trademark of Artimplant AB. SportMesh[TM] is a trademark of Arthrotek, Inc. About Artimplant: Artimplant restores health by offering degradable de·grad·a·ble adj. That can be chemically degraded: degradable plastic wastes. de·grad implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs in a growing number of therapy areas. Our motto is "Help the body to heal". Artimplant is a public company listed on the Nordic Exchange. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. The following files are available for download: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=36 8472&fn=wkr0001.pdf (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion